NovoCure NVCR
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
NovoCure (NVCR) Business Model and Operations Summary
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Key Insights
NovoCure (NVCR) Core Market Data and Business Metrics
Latest Closing Price
$16.49Market Cap
$1.78 BillionPrice-Earnings Ratio
-29.45Total Outstanding Shares
107.61 Million SharesTotal Employees
1,453Dividend
No dividendIPO Date
October 2, 2015SIC Description
Surgical & Medical Instruments & ApparatusPrimary Exchange
NASDAQHeadquarters
No. 4 The Forum, St. Helier, Y9, JE2 4UF
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities | $10.19 Million |
| Net Cash Flow | $20.76 Million |
| Exchange Gains/Losses | $87,000 |
| Net Cash Flow From Operating Activities | $10.38 Million |
| Net Cash Flow, Continuing | $20.67 Million |
| Net Cash Flow From Financing Activities, Continuing | $100,000 |
Income Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Basic Earnings Per Share | $-0.28 |
| Research and Development | $51.88 Million |
| Benefits Costs and Expenses | $176.68 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Net Income/Loss | $-30.57 Million |
| Income/Loss From Continuing Operations Before Tax | $-21.59 Million |
Comprehensive Income
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-1.86 Million |
| Comprehensive Income/Loss | $-32.43 Million |
| Comprehensive Income/Loss Attributable To Parent | $-32.43 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Assets | $1.22 Billion |
| Noncurrent Assets | $126.72 Million |
| Equity | $360.78 Million |
| Inventory | $39.10 Million |
| Noncurrent Liabilities | $126.20 Million |
| Liabilities And Equity | $1.22 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||